Labcorp Holdings Inc.
LH · NYSE
LH · NYSE
Labcorp provides diagnostic laboratory testing and laboratory services for drug development through its Diagnostics and Biopharma Laboratory Services segments. Diagnostics processes tests used in patient care, serving healthcare providers, health systems, patients and other customers through its laboratory network. Biopharma Laboratory Services supports pharmaceutical and biotechnology companies with services used in developing medicines. The company earns revenue by performing tests and providing research and development services. Its scale is reflected in FY2025 revenue of $14.0 billion and net income of $0.9 billion, up from $13.0 billion and $0.7 billion, respectively, in FY2024. The supplied evidence does not give a revenue split between the two segments.
Labcorp rose 11.59% over the week, from $329.93 to $368.16. Shares were nearly flat Monday and Tuesday, then jumped to $360.25 Wednesday after the company reported third-quarter results and raised its 2026 outlook; they added further ground Thursday. The earnings report was the decisive catalyst: revenue reached $3.81 billion, up 6.9% year over year, and adjusted earnings and revenue beat estimates by 2.80% and 1.13%, respectively. Labcorp also reported growth in both segments and margin expansion, while highlighting double-digit adjusted EPS growth and a higher full-year guidance midpoint. There was no material reversal after the earnings-driven jump.
